Dexmedetomidine and remazolam in the treatment of agitated delirium in ICU adult patients: a randomized controlled trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052192

Enrollment

Unknown

Registered

2021-10-22

Start date

2021-12-01

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

delirium

Interventions

Experimental group1:remazolam

Experimental group2:dexmedetomidine

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients admitted to ICU, aged >=18 years; 2. RASS score >= 2 points; 3. CAM-ICU suggests the presence of delirium.

Exclusion criteria

Exclusion criteria: 1. Are receiving dexmedetomidine or remazolam treatment; 2. Pregnant or breastfeeding; 3. Those with hearing or visual impairment who cannot communicate; 4. Sick sinus syndrome, heart rate < 50 beats/min, or second degree or above heart block without a pacemaker; 5. Severe hepatic insufficiency (Child-Pugh grade C); 6. Past history of schizophrenia, epilepsy, Parkinson's disease or myasthenia gravis; 7. Changes in the state of consciousness after traumatic brain injury or neurosurgery; 8. Hypersensitivity or contraindication to a2 adrenergic agonists or benzodiazepines; 9. Has participated in other clinical trials; 10. Patients who do not agree to participate in this trial.

Design outcomes

Primary

Measure	Time frame
the time for delirium recovery;	—

Countries

China

Contacts

Public ContactHe Dehua

The Affiliated Hospital of Guizhou Medical University

1635543116@qq.com+86 18111842113

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026